{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:56Z","timestamp":1793776376136,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Start-up Fund for High-level Talent at the Second Affiliated Hospital of Wannan Medical College","award":["GRK202510"],"award-info":[{"award-number":["GRK202510"]}],"id":[{"id":"https:\/\/ror.org\/037ejjy86","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Start-up Fund for High-level Talent at the Second Affiliated Hospital of Wannan Medical College","award":["GRK202511"],"award-info":[{"award-number":["GRK202511"]}],"id":[{"id":"https:\/\/ror.org\/037ejjy86","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82501744"],"award-info":[{"award-number":["82501744"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Liaoning Provincial Natural Science Foundation Joint Funds Project","award":["2024-BSLH-047"],"award-info":[{"award-number":["2024-BSLH-047"]}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJ212510161032"],"award-info":[{"award-number":["LJ212510161032"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Scientific Research Project of the Anhui Province Department of Education","award":["2024AH040242"],"award-info":[{"award-number":["2024AH040242"]}]},{"name":"High-level Talent Recruitment Program of Wannan Medical College","award":["EYR202306"],"award-info":[{"award-number":["EYR202306"]}],"id":[{"id":"https:\/\/ror.org\/037ejjy86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early detection of Alzheimer's disease (AD) pathology in cognitively unimpaired individuals is critical for preclinical intervention. Plasma biomarkers, especially phosphorylated tau217 (p-tau217), are promising predictors of amyloid-\u03b2 (A\u03b2) accumulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cohort study, we analyzed data from cognitively unimpaired older adults in the A4 and LEARN studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,407), comprising 452 participants with A\u03b2 positron emission tomography (PET)-negative status and 955 participants with A\u03b2 PET-positive status. We evaluated the accuracy of plasma biomarkers (p-tau217, p-tau181, A\u03b242\/40 ratio, and others) in predicting A\u03b2 PET positivity using receiver operating characteristic analysis, comparing covariate-adjusted individual biomarker and biomarker-ratio models with a multivariable combined model integrating plasma biomarkers and covariates. (age, sex, apolipoprotein E [APOE] \u03b54 genotype).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma p-tau217 showed the strongest individual association with A\u03b2 PET status (area under the curve [AUC], 0.85). A combined model integrating p-tau217, p-tau181, A\u03b242, age, sex, and APOE \u03b54 achieved the highest overall discrimination (AUC, 0.87), although the improvement over the covariate-adjusted p-tau217 model was modest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma p-tau217 showed the strongest individual performance for predicting A\u03b2 PET positivity in cognitively unimpaired older adults. Adding other plasma biomarkers and clinical covariates provided a modest incremental improvement in classification performance. These findings support blood-based prescreening as a potential enrichment approach, while indicating that confirmatory amyloid assessment remains necessary when definitive A\u03b2 status is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02080-x","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:45:33Z","timestamp":1779277533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Plasma p-tau217, p-tau181, and A\u03b242 predict amyloid PET positivity in cognitively unimpaired adults"],"prefix":"10.1186","volume":"18","author":[{"given":"Rui","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the A4 and LEARN Study; The Health and Aging Brain Study (HABS-HD) Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid E","family":"O\u2019Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Toga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Braskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braskie","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"McColl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Large","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badri","family":"Vardarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Rivera Mindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mapstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozioma","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Vintimilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Borzage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau","family":"Ances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Babulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Llibre-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Vig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2080_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"2080_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"2080_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3:506\u201319.","journal-title":"Nat Aging"},{"key":"2080_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363.","journal-title":"Nat Med"},{"key":"2080_CR5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395.","journal-title":"Nat Med"},{"key":"2080_CR6","doi-asserted-by":"crossref","unstructured":"Zabala-Findlay A, Penny LK, Lofthouse RA, Porter AJ, Palliyil S, Harrington CR, Wischik CM, Arastoo M: Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer\u2019s Disease: Systematic Review and Meta-Analysis. Cells. 2023;12(8):1184.","DOI":"10.3390\/cells12081184"},{"key":"2080_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70707","volume":"21","author":"JD Doecke","year":"2025","unstructured":"Doecke JD, Chenna A, Lo M, Badal Y, Yee B, Martone R, et al. Combining Lumipulse p-tau217 and A\u03b242\/40 as confirmatory tests for A\u03b2 positivity prior to disease-modifying therapy. Alzheimers Dement. 2025;21:e70707.","journal-title":"Alzheimers Dement"},{"key":"2080_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","volume":"81","author":"S Janelidze","year":"2024","unstructured":"Janelidze S, Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, Palmqvist S, Mattsson-Carlgren N, et al. Plasma phosphorylated Tau 217 and A\u03b242\/40 to predict early brain A\u03b2 accumulation in people without cognitive impairment. JAMA Neurol. 2024;81:947\u201357.","journal-title":"JAMA Neurol"},{"key":"2080_CR9","doi-asserted-by":"crossref","unstructured":"Malek-Ahmadi M, Sharma S, Stipho F, Denkinger M, Singh A, Brum WS, Ashton NJ: Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis. JAMA Neurol. 2025;83(1):13\u201319.","DOI":"10.1001\/jamaneurol.2025.4721"},{"key":"2080_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol. 2019;76:1060\u20139.","journal-title":"JAMA Neurol"},{"key":"2080_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"2080_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dor\u00e9 V, et al. Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19:1117\u201334.","journal-title":"Alzheimers Dement"},{"key":"2080_CR13","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/brain\/awaf033","volume":"148","author":"J Fern\u00e1ndez Arias","year":"2025","unstructured":"Fern\u00e1ndez Arias J, Brum WS, Salvad\u00f3 G, Therriault J, Servaes S, Wang YT, et al. Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer\u2019s disease spectrum. Brain. 2025;148:2384\u201399.","journal-title":"Brain"},{"key":"2080_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, Mattsson-Carlgren N, Bali D, Ordu\u00f1a Dolado A, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025;148:416\u201331.","journal-title":"Brain"},{"key":"2080_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"2080_CR16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaneurol.2025.2974","volume":"82","author":"PS Insel","year":"2025","unstructured":"Insel PS, Mattsson-Carlgren N, Langford O, Caruso VM, Leuzy A, Young CB, et al. Concurrent changes in plasma phosphorylated tau 217, tau PET, and cognition in preclinical Alzheimer disease. JAMA Neurol. 2025;82:985\u201393.","journal-title":"JAMA Neurol"},{"key":"2080_CR17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.neuron.2024.02.017","volume":"112","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhang W, Ming C, Gao X, Yuan H, Lin X, et al. P-tau217 correlates with neurodegeneration in Alzheimer\u2019s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. Neuron. 2024;112:1676-1693.e1612.","journal-title":"Neuron"},{"key":"2080_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389:1096\u2013107.","journal-title":"N Engl J Med"},{"key":"2080_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44:825\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2080_CR20","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72-83.","journal-title":"Alzheimers Dement"},{"key":"2080_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"2080_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, et al. Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimers Dement. 2025;21:e70038.","journal-title":"Alzheimers Dement"},{"key":"2080_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"2080_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332:1245\u201357.","journal-title":"JAMA"},{"key":"2080_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"2080_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Su\u00e1rez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024;20:426\u201339.","journal-title":"Nat Rev Neurol"},{"key":"2080_CR27","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1002\/alz.14150","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, et al. Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:8209\u201315.","journal-title":"Alzheimers Dement"},{"key":"2080_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14430","volume":"21","author":"M Olvera-Rojas","year":"2025","unstructured":"Olvera-Rojas M, Sewell KR, Karikari TK, Huang H, Oberlin LE, Zeng X, et al. Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/A\u03b242. Alzheimers Dement. 2025;21:e14430.","journal-title":"Alzheimers Dement"},{"key":"2080_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70288","volume":"21","author":"GE Ennis","year":"2025","unstructured":"Ennis GE, Norton D, Langhough RE, Gooding DC, Carter FP, Wilson R, et al. The performance of plasma p-tau217 in Black middle-aged and older adults. Alzheimers Dement. 2025;21:e70288.","journal-title":"Alzheimers Dement"},{"key":"2080_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P, et al. Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. 2025;31:2036\u201343.","journal-title":"Nat Med"},{"key":"2080_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14458","volume":"21","author":"M Khalafi","year":"2025","unstructured":"Khalafi M, Dartora WJ, McIntire LBJ, Butler TA, Wartchow KM, Hojjati SH, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimers Dement. 2025;21:e14458.","journal-title":"Alzheimers Dement"},{"key":"2080_CR32","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement. 2024;20:8074\u201396.","journal-title":"Alzheimers Dement"},{"key":"2080_CR33","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","volume":"20","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Griswold M, Bornhorst JA, Graff-Radford J, Ramanan VK, Vemuri P, et al. Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. Alzheimers Dement. 2024;20:6506\u201316.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02080-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02080-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02080-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:02:21Z","timestamp":1780437741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02080-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02080-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8587114\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from an institutional review board was obtained at each of the sites and all participants and their study partners provided written informed consent prior to data collection. Ethical approval for this study was obtained in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}